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Abstract 
The neuron is the target of inflammatory demyelinating processes in multiple sclerosis (MS). 
In progressive MS, however, there is a gathering body of evidence indicating that molecular 
changes converge on mitochondria within neuronal cell bodies. The most reproducible 
change relates to mitochondrial respiratory chain complex deficiency, which compromises 
the capacity of neurons to generate ATP. The resulting energy failure state is coupled with 
an increase in demand for energy by the demyelinated axon, being particularly relevant to 
the long tracts such as corticospinal tracts with long projection axons. Recent work in our 
laboratory and that of our collaborators indicates the limited reflection of the mitochondria 
changes within neurons in experimental disease models. The mitochondrial changes within 
neuronal compartments are likely to offer novel targets for the improvement in neuronal 
function in patients with progressive MS. 
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Introduction 
Progressive multiple sclerosis (MS) is a chronic inflammatory demyelinating disorder with 
ongoing neurodegeneration.(Stadelmann 2011) Inflammation is a potent inducer of damage 
to neurons, particularly axons and synapses in MS. Furthermore, the restoration of myelin to 
denuded axons (remyelination) is limited in progressive MS, which leaves the naked axons 
much more vulnerable to additional insults. There is an overall tendency for inflammation to 
become less prominent with increasing disease duration, although with case-to-case 
variability even at the end stage of the disease.(Mahad et al. 2015) In contrast to 
inflammation, the lesion burden or the extent of demyelination gradually increases partly due 
to lack of remyelination as well as ongoing and repeated inflammatory demyelination. The 
cumulative impact of inflammation and chronic demyelination leads to the loss of CNS 
tissue, as reflected by brain and spinal cord atrophy. Neuropathological studies indicate 
extensive loss of axons particularly in the spinal cord long tracts and synapses in the grey 
matter (>60-70% loss).(Bjartmar et al. 2003; Jurgens et al. 2016) In contrast, the extent of 
neuronal cell body loss in the cortical grey matter is marginal, with 15-20% loss, except in 
cases with so called follicle-like B cell infiltrated in the meninges.(Magliozzi et al. 2010) The 
existence of neuronal cell bodies at the end stage of progressive MS in autopsy tissue offers 
the opportunity to study their content and gain insight into how the neurons may play a role 
in and contribute to the neurodegenerative process of progressive MS. 
 
 We discuss the molecular, proteomic, biochemical and dynamic mitochondrial changes that 
are intrinsic to neurons, (Mahad et al. 2015) and how these molecular changes lead to an 
energy failure state through an increase in demand for ATP and a decrease in capacity to 
produce ATP by mitochondria. 
 
Molecular changes within the neuronal cell bodies in progressive MS 
It is abundantly clear that the mitochondria within neuronal cell bodies are damaged in 
progressive MS (Figure 1). All these molecular changes, discussed in more detail below, 
converge on mitochondrial function and transport. The molecular changes within neurons in 
progressive MS impact the mitochondrial respiratory chain complexes and hence the ability 
to produce ATP by oxidative phosphorylation. 
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Mitochondrial respiratory chain complexes in neuronal cell bodies 
The first detailed study of upper motor neurons from non-demyelinated motor cortex was 
reported by Dutta et al just over a decade ago.(Dutta et al. 2006) These authors subjected 
well-preserved grey matter tissue from rapid autopsy cases to microarrays in an unbiased 
manner and found the majority of the most significant molecular changes to be related to the 
mitochondrial respiratory chain complex subunits. They investigated nuclear DNA encoded 
transcripts and found 26 transcripts of mitochondrial respiratory chain complexes to have 
decreased significantly. This decrease in nuclear DNA encoded mitochondrial transcripts 
was neuron-specific and affected the majority of upper motor neurons. Furthermore, the 
transcript changes led to mitochondrial respiratory chain complex I and complex III 
deficiency. Notably, the mitochondrial respiratory chain deficient neurons were found in non-
demyelinated motor cortex, which suggests a role for pathological processes such as 
demyelination of the axon in the white matter in the generation of neuronal mitochondrial 
defects in MS.  
Since the publication of the above study in 2006, the decrease in nuclear DNA encoded 
mitochondrial respiratory chain transcripts in non-demyelinated cortex has been observed by 
others.(Broadwater et al. 2011; Witte et al. 2013) An independent group identified the 
transcripts of mitochondrial respiratory chain complexes to have significantly decreased in 
both the cingulate gyrus and frontal cortex.(Witte et al. 2013) Furthermore, authors of this 
study identified a significant decrease (quarter to one third) in mRNA level of peroxisome 
proliferator-activated receptor (PPAR)-gamma coactivator 1-alpha (PGC-1alpha), a master 
regulator of metabolism and mitochondrial function. The decrease in PGC-1alpha was 
evident in the deeper cortical layers (layers IV-VI).  The mitochondrial respiratory chain 
complex deficiency in non-demyelinated motor cortex was associated with a decrease in 
components of GABAergic neurotransmission and loss of inhibitory interneuron processes 
as well as a decrease in mitochondrial anti-oxidants.(Dutta et al. 2006; Witte et al. 2013) 
Broadwater and colleagues undertook a different experimental approach to investigate 
mitochondria in the non-demyelinated cortex in progressive MS cases.(Broadwater et al. 
2011) Using mass spectroscopy they identified proteomic changes relating to the 
mitochondrial respiratory chain complexes in the normal appearing motor cortex in 
progressive MS. A significant decrease in mitochondrial respiratory chain complex IV subunit 
V was confirmed by western blots. Furthermore, another study indicated a number of 
nuclear DNA encoded and mitochondrial DNA encoded transcripts to have decreased in 
acute white matter MS lesions.(Fischer et al. 2012) 
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Our study undertook a single cell approach and interrogated mitochondrial DNA and 
identified neurons in the deeper cortical layers that lacked complex IV and contained 
complex II, which in the literature are termed as respiratory deficient neurons.(Campbell et 
al. 2011) Laser micro-dissection of these respiratory deficient neurons and detailed analysis 
of mitochondrial DNA extracted from the captured cell identified clonally expanded 
mitochondrial DNA deletions at high heteroplasmy level. Heteroplasmy is when  
mitochondrial DNA mutation(s) co-exist with wild type genomes in a single cell.(Larsson 
2010) The proportion of mitochondrial DNA mutations to total mitochondrial DNA content in 
a single cell designates the heteroplasmy level.(Larsson 2010) The process that leads to the 
increase in the copy number of mutant mitochondrial genomes in a single cell is termed 
clonal expansion of mitochondrial DNA mutation. Clonal expansion of mitochondrial DNA is 
well recognized in a number of neurodegenerative conditions, although the mechanism is 
not well-understood.(Larsson 2010) Judging by the current understanding of the time course 
of clonal expansion of mitochondrial DNA deletion in single cells, we expect it to occur over 
years in progressive MS. These respiratory deficient neurons, also reported in a number of 
classical neurodegenerative disorders, were more prevalent in non-demyelinated motor 
cortex and were not directly associated with microglia.(Campbell et al. 2011) These 
observations widen the possible causes and indicate an irreversible respiratory deficiency 
within neurons in progressive MS. 
 
We then investigated the choroid plexus and skeletal muscle, which contain metabolically 
highly active post-mitotic cells, to extend the study of respiratory deficiency and 
mitochondrial DNA deletions in progressive MS to non-neuronal cells. Respiratory deficient 
choroid plexus epithelial cells were much more frequent in progressive MS cases compared 
with controls, Alzheimer’s disease and Parkinson’s disease.(Campbell et al. 2012) Again, we 
detected high heteroplasmy level of clonally expanded mitochondrial DNA deletions in the 
respiratory chain deficient cells. In contrast, we did not detect a significant change in the 
extent of respiratory deficient muscle fibres in progressive MS compared with age-matched 
controls.(Campbell et al. 2013) These findings suggest that the mitochondrial changes 
observed within neuronal cell bodies in progressive MS are likely to have been induced 
within the CNS, rather than representative of a multi-organ disorder with an inherited 
aetiology. 
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The cause(s) of these molecular changes intrinsic to neurons in progressive MS is not 
known, whether this is a primary effect or a secondary phenomenon following the loss of 
functional connectivity due to the loss of synapses and transection of the long projecting 
axon. In terms of the mitochondrial DNA deletions, the molecular events encompass a likely 
active or a positive selection phenomenon and the resulting mitochondrial respiratory chain 
complex deficiency is irreversible. Further studies are needed to understand both the cause 
of the neuronal molecular changes and the consequences of the neuronal mitochondrial 
respiratory chain deficiency,  
 
Mitochondrial transport machinery within neurons in progressive MS 
Beside the studies that found mitochondrial respiratory chain complex deficiency, other 
independent groups have identified changes that impact on the transport,of mitochondria 
from the cell body to the axon.  
 
A study that investigated histone deacetylase 1 (HDAC1), which is an enzyme that is found 
within the nucleus and represses nuclear DNA transcription, detected aberrantly located 
enzyme in the cytoplasm and degenerated axons in MS autopsy tissue as well as in an in 
vivo experimental system with cuprizone induced demyelination.(Kim et al. 2010) This 
nuclear export of HDAC1 was neuron specific, related to the increase in calcium entry into 
the neuron and occurred prior to the damage to neuritis. The cytoplasmic HDAC1 formed 
protein complexes with kinesins (KIF2A and KIF5), which are motor proteins involved in 
anterograde transport of protein complexes, mRNA and membranous organelles, such as 
mitochondria, in axons. This interaction between cytoplasmic HDAC1 and kinesins, following 
exposure of neurons to glutamate and TNFalpha, impaired the anterograde transport of 
mitochondria in the axon. The inhibition of the nuclear export of HDAC1 using 
pharmacological agents prevented the damage to neurites. The impaired mitochondrial 
transport within axons in the context of inflammation was confirmed in experimental 
autoimmune encephalomyelitis (EAE) by another group.(Sorbara et al. 2014) Both 
anterograde and retrograde transport of mitochondria within axons was significantly 
decreased by a slower speed and more frequent stops. The transport deficits in EAE were 
rescued by methylprednisolone and redox scavengers. Further evidence of impaired 
anterograde transport of mitochondria in progressive MS is indicated by the significant 
decrease in motor proteins, called kinesins (KIF5A, KIF21B and KIF1B), within 
neurons.(Hares et al. 2013)  
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
The impaired anterograde transport of mitochondria in neurons compromises the ability of 
the neuronal cell body to replenish the axon with new mitochondria. Whether agents, such 
as glucocorticoids, redox scavengers and anti-inflammatory drugs, that improve 
mitochondrial transport protect axons in progressive MS needs to be assessed in future 
studies. Furthermore, whether the manipulation of mitochondria protects demyelinated 
axons requires further investigation in pre-clinical systems that model the neuronal 
mitochondrial changes that are described in progressive MS. 
 
Mitochondrial changes within demyelinated axons in MS 
The energy demands and the distribution of mitochondria in the myelinated axon 
A number of studies carried out over the past decade has shown evidence of mitochondrial 
changes within the demyelinated axon. To understand the significance of these changes, it 
is important to recognise the role mitochondria have to play in the myelinated axon within the 
CNS. Directed by the requirement for energy, the precise location of mitochondria within the 
axoplasm is crucial to axonal function.  
The major advantage of myelination of axons is the saltatory conduction of action potentials 
which results in their fast propagation along the nerve. Recent evidence also suggests that 
myelinating cells of the CNS, the oligodendrocytes, supply axonal mitochondria with the 
metabolites required for them to efficiently perform oxidative phosphorylation to produce 
ATP, the cellular energy currency.(Funfschilling et al. 2012) Within the myelinated axoplasm, 
mitochondria are far from uniform, differing in morphology and velocity most often depending 
on their location, whether at the node of Ranvier, paranode, juxtanode or internode where 
changes in calcium levels and energy demand are different. It has been reported that the 
highly energy demanding Na+/K+ ATPase is richly distributed along the internode and 
juxtaparanode axonal membrane whilst absent from the nodal space and paranode.(Young 
et al. 2008) These changes are reflected in the distribution of mitochondria which varies 
dramatically along the axon. A third of nodes of Ranvier in mouse myelinated axons contain 
no mitochondria whilst the majority of the remaining nodes contain only a single 
mitochondria.(Ohno et al. 2011) Both the length and volume of mitochondria within the node 
and paranode are significantly decreased compared to their counterparts in the 
juxtaparanode and internode. In these regions, where large stationary mitochondrial 
networks are found, the ratio of mitochondrial to axonal volume is significantly increased.  
The variable distribution of the mitochondria is therefore likely to result from the changeable 
energy demands along the axon. It has also been hypothesized that axonal Ca2+ is 
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responsible for the distribution of mitochondria along the axon. Peripheral nervous system 
(PNS) axons show a marked increase in calcium signaling at the node of Ranvier,(Zhang et 
al. 2010) where mitochondria are highly enriched whilst in vitro evidence also suggests 
similar role of axoplasmic Ca2+ in the CNS.(Ohno et al. 2011) The mechanism for this may 
be an interaction of Ca2+ with the microtubule motor kinesin-1 responsible for anterograde 
transport of mitochondria along the axon.(Saotome et al. 2008) Whilst only shown in the 
peripheral nervous system (PNS) to date, artificial stimulation of the Na+/K+ ATPase has also 
been shown to enhance retardation of mitochondrial velocity.(Zhang et al. 2010) 
Experimentally blocking action potentials results in a decrease in mitochondrial movement, 
whilst enhancing neuronal firing increases the mitochondrial movement, which suggests a 
likely role for axonal electrical conductivity in mitochondrial distribution.  
 
Many of these factors become increasingly important, as dramatic axonal metabolic changes 
in the event of demyelination lead to important modifications in mitochondrial dynamics. 
 
The changing energy demands of the demyelinated axon 
Unmyelinated axons (axons that are never myelinated) provide a useful guide as to the 
prediction of mitochondrial changes one might observe in the demyelinated axon.(Bristow et 
al. 2002) Studies of the unmyelinated axons of the lamina cribrosa (site where axons exit the 
eye posteriorly to join the optic nerve) have provided such information where complex IV 
activity has been investigated. Complex IV is the terminal subunit in the electron transport 
chain and consumes 90% of cellular oxygen. The unmyelinated segment of the lamina 
cribrosa was found to have increased complex IV activity compared to its myelinated 
counterpart, an indicator of increased energy demand, highlighted by the uniform distribution 
of certain isoforms of Na channels (Nav 1.1 and Nav1.6) along the unmyelinated 
segment.(Bristow et al. 2002; Balaratnasingam et al. 2009) This is in contrast to myelinated 
axons where Na channels are specifically localized to the nodes of Ranvier within the CNS. 
The early redistribution of Na channels along the denuded axonal segment has been shown 
to be a consistent feature of demyelinated axons, which may allow the continuation of action 
potentials and in the context of MS, recovery of clinical function.(Craner et al. 2004b) The 
increase of complex IV activity has also been noted in animal models of dysmyelination 
(abnormal myelination, where the myelin sheaths are relatively thin, compared with normally 
myelinated axons) resulting from the loss of myelin basic protein and overexpression of 
proteolipid protein, respectively.(Andrews et al. 2006; Hogan et al. 2009) In both models, an 
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increase of axonal mitochondrial content was observed. It may be that the increase in axonal 
complex IV plays an important role, highlighted by the fact that in an animal model of only 
partial demyelination, caused by the hemizygous overexpression of PLP, an increase of 
mitochondrial content without complex IV activity was associated with axonal degeneration.  
An increase in axonal mitochondrial content is a consistent feature of animal models of 
demyelination. Our recent studies (unpublished) show that this encompasses the classic 
modes of demyelination including lysolecithin, lipopolysaccharide, cuprizone, and various 
forms of EAE. It is now established that this is a feature of morphologically intact, large 
caliber axons in demyelinated lesions of MS (Figure 2). An increase in the axon-specific 
mitochondrial docking protein, syntaphilin, suggests that these mitochondria are likely to be 
stationary.(Mahad et al. 2009) In vitro evidence has provided further details of these 
changes including an increased size of stationary mitochondria in demyelinated axons, 
induced by lysolecithin and velocity of motile mitochondria.(Kiryu-Seo et al. 2010) It is 
perhaps surprising to note that the actual number of stationary mitochondria did not change, 
rather it is hypothesized that newly formed mitochondria fuse with those already at stationary 
sites along the axon. All of these changes were found to be reversed, in vitro, upon 
remyelination. This may not be entirely the case in vivo where axonal mitochondrial content 
does not return to baseline, intriguingly suggesting that remyelinated axons have different 
energy demands compared to myelinated axons, in vivo.(Zambonin et al. 2011) 
 It has been a matter of debate as to whether these mitochondrial changes in response to 
demyelination represent a compensatory or pathological phenomenon. Evidence does 
suggest, at least in the short-term, that these changes are essential for survival of the axon. 
Histological evidence from MS lesions indicates that axons that have morphological signs of 
degeneration and transport block do not show any increase in mitochondrial content.(Mahad 
et al. 2009) When the mitochondrial response to demyelination in axons is blocked, 
evidence for increased axon stress is observed and the experimental loss of syntaphilin, 
results in an increase of axonal degeneration.(Kiryu-Seo et al. 2010; Ohno et al. 2014) In the 
long-term however, recent evidence points toward a potential detrimental outcome for the 
accumulation of mitochondria in demyelinated axons. When syntaphilin was knocked out in 
the Shiverer dysmyelinated model an improved clinical outcome was noted with less axon 
degeneration. Thus, the degradation of unhealthy mitochondria, which can produce harmful 
ROS over a prolonged period of time, is likely to be important for the survival of 
demyelinating axons.(Joshi et al. 2015)    
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Axon degeneration in progressive MS - a specific role for complex IV activity? 
Axon degeneration is a significant pathological hallmark of MS, its importance highlighted by 
the hypothesis that axon loss is the crucial factor in the development of progressive MS from 
relapsing-remitting disease.(Bjartmar et al. 2003) Inflammation is a key cause of axon 
degeneration particularly during the initial stages of disease. Anti-inflammatory treatments, 
effective during the acute stage of disease are rendered redundant in the progressive stage 
of disease, the reasons for which remain unresolved. Chronic demyelinated lesions persist 
for decades and slow burning axonal degeneration persists in such chronic MS lesions. One 
hypothesis for inflammation-independent axon degeneration is that the neuronal 
mitochondrial dysfunction leads to a lack of ATP in the axon and the loss of Na+/K+ ATPase 
activity, which is essential to maintain ionic balance in demyelinated axons (Waxman 2006). 
An increase of axonal calcium, exacerbated by mitochondrial dysfunction can activate a 
number of degenerative pathways. Evidence from MS postmortem tissue supports this 
mechanism. Degenerative axons are associated with co-localization of Nav1.6 channels and 
the Na+/Ca2+ exchanger.(Craner et al. 2004a)  
Histological studies of human MS and animal model tissue also highlight the potential 
importance of complex IV activity over mitochondrial content. Degenerating axons in MS do 
not show the compensatory increase of axonal mitochondrial content nor complex IV activity 
but further studies suggest it is complex IV activity rather than mitochondrial content that is 
the more important factor.(Mahad et al. 2009) In the hemizygous PLP overexpression 
mouse model, axon degeneration was apparent in the light of an increase in mitochondrial 
content but no concurrent increase of complex IV activity.(Hogan et al. 2009) Our recent 
studies (unpublished) show that despite the fact that all classic demyelination animal models 
show an increase of axonal mitochondrial content upon demyelination, this is not always the 
case for complex IV activity. Following lysolecithin induced demyelination both mitochondrial 
content and complex IV activity increase within demyelinated axons. In contrast, we did not 
find a corresponding increase in complex IV activity within demyelinated axons in a number 
of EAE in mouse, rat and marmoset species, despite an increase in axonal mitochondrial 
content. Interestingly, the level of axonal of complex IV activity was significantly correlated 
with the amount of axonal damage within the demyelinated lesion, which was not the case 
for the amount of axonal mitochondrial content. Future studies should focus on the timing of 
complex IV loss and its relation to changes in axonal calcium level, mitochondrial reactive 
oxygen species production as well as mitochondrial membrane potential. Evidence from 
EAE suggests that the loss of axonal complex IV activity occurs relatively early compared 
with structural changes. The loss of complex IV activity in axonal mitochondria in EAE may 
precede axonal mitochondrial morphological changes.(Nikic et al. 2011) The mechanism of 
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complex IV activity loss may be nitration of complex IV subunit IV that occurs in EAE prior 
even to the arrival of inflammatory cells.(Qi et al. 2006) 
 
The increased energy demand of demyelinated axons, highlighted by changes in the 
mitochondrial network, must be met by the neuronal cell body, the site of mitochondria 
generation (Figure 2). The dysfunction of the mitochondria in neuronal soma would therefore 
put the demyelinated axon at risk of degeneration.  
 
Are the molecular changes intrinsic to neurons in progressive MS primary or 
secondary? 
The nature of the autopsy tissue available in progressive MS makes the delineation of the 
time course of the neuron-specific irreversible mitochondrial injury challenging. Although 
biopsy material from early stage of MS has been used to define inflammation in the cortex 
such material is limited for more detailed analysis of mitochondria within neuronal cell 
bodies.(Lucchinetti et al. 2011) Inflammation is a potent inducer of reactive oxygen species 
and mitochondrial dysfunction in the CNS. Suppressing inflammation is an obvious strategy 
to limit or prevent mitochondrial dysfunction and facilitate the generation of healthy 
mitochondria in the surviving neurons. In progressive MS, however, our current view is that 
at least part of the molecular changes within neuronal cell bodies that compromise the 
mitochondrial respiratory chain are induced and irreversibly amplified within the CNS by the 
chronic inflammation and demyelination. Iron accumulation and increase in oxidative injury 
are likely to further amplify the mitochondrial damage over time. Chronic demyelination, as 
mentioned above, will be another factor that will trigger axonal mitochondrial injury 
independent of inflammation, as shown in Shiverer mice.(Joshi et al. 2015) Given the 
protracted clinical course of relapsing MS, the compromise of the neuronal compartment due 
to mitochondrial dysfunction may occur relatively early in progressive MS. 
 
Therapeutic implication of the neuronal mitochondrial respiratory chain complex 
deficiency. 
Immunomodulation has been a very successful strategy in relapsing MS and increasingly at 
least in a subset of patients with progressive MS. Drugs and monoclonal antibodies that 
target remyelination are currently being tested in clinical trials and appear to be a promising 
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strategy to protect axons in MS.(Franklin et al. 2012) We see the targeting of the neuronal 
bioenergetics, by improving mitochondrial function and dynamics, as an addition to the 
future combinatorial therapeutic strategies for progressive MS. In this respect, experimental 
disease models that reflect the inflammatory component as well as chronic demyelination 
and neuron specific mitochondrial injury are a much needed resource to both increase the 
understanding of the pathogenesis of progressive MS and to develop novel therapeutic 
strategies and agents. 
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Figure legends 
Figure 1 
 
 
 
Figure 1. Molecular changes that are intrinsic to neuronal cell bodies in MS. A number of 
studies have now identified molecular changes, all o f which converge on mitochondria, in 
progressive MS. Dutta et al described a decrease in nuclear DNA encoded transcripts of 
mitochondrial respiratory chain complexes, which was reproduced by others. Witte et al 
proposed a decrease in PGC-1alpha as a possible cause of the decrease in nuclear 
encoded transcripts within neurons. Campbell et al identified clonally expanded 
mitochondrial DNA deletions (mtDNA) at high heteroplasmy level within single neurons in 
progressive MS cortex. Other studies reported molecular changes that impair anterograde 
transport of mitochondria, decrease in HDAC1 and kinesins, which are essential for 
replenishing the axon with healthy mitochondria in physiological conditions. In progressive 
MS, the respiratory chain complex deficiency means that the neuronal cell body is no longer 
capable of replenishing the axon with healthy mitochondria, particularly in long projection 
axons such as those in the corticospinal tracts (see Figure 2). Red: respiratory chain 
complex deficient mitochondria. Green: healthy mitochondria. 
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Figure 2 
 
 
Figure 2. How neuronal mitochondria play a role in axon degeneration in progressive MS: A. 
We reported the gathering of functional mitochondria in the demyelinated axon in MS and 
upon non-autoimmune demyelination of wild type neurons in vivo, as previously published 
(Mahad et al. 2015). These mitochondrial changes (increased number, size, activity and 
speed of movement of mitochondria reported as “axonal mitochondrial response to 
demyelination”) protected the demyelinated axon since the inability to mount the axonal 
mitochondrial response to demyelination in mice lacking syntaphilin, an axon specific 
mitochondria docking protein, led to an excess of axon ovoids upon demyelination. B. During 
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pre-progressive stage of MS, inflammatory products injure mitochondria in multiple cell types 
including neurons and the oxidative injury to DNA leads to the formation of mtDNA deletions 
in both the white matter (1) and grey matter. Over time and with age abnormal mitochondria 
are amplified in neuronal cell bodies (2), for example, through clonal expansion of the 
inflammation induced mtDNA deletions and depleted nuclear DNA encoded mitochondrial 
transcripts. C. The resulting biochemical deficiency of the mitochondrial respiratory chain 
complexes or enzymes in neuronal cell bodies (indicated by the texture grey background) 
then act as a reservoir of abnormal mitochondria, which then undergo aberrant placement to 
the demyelinated axon and cause energy failure and increased reactive oxygen species 
production in the axon (3). In addition, any residual or active inflammation in progressive MS 
brain would further impair mitochondrial function particularly at the active edge of chronic 
active MS lesions. This forms a three step hypothesis (formation, amplification and 
displacement) for the role of mitochondria in axon degeneration in progressive MS. Arrows 
indicate the process through which the three step hypothesis leads to axon energy failure in 
progressive MS. 
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